GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HM11260C

Company
Hanmi Pharmaceutical Company Limited
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for HM11260C and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT07379333

    A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

    Not yet reported Hanmi Pharmaceutical Company Limited 118 participants Est. completion 2028-01 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT01093729

    A Study of HM11260C in Healthy Male Subject

    Not yet reported Hanmi Pharmaceutical Company Limited 41 participants Est. completion 2010-10 Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT01452451

    Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

    Not yet reported Hanmi Pharmaceutical Company Limited 72 participants 1 site
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02057172

    Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

    Not yet reported Hanmi Pharmaceutical Company Limited 254 participants Est. completion 2014-12 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Status unknown NCT NCT02059564

    A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

    Not yet reported Hanmi Pharmaceutical Company Limited 44 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT02075281

    Effect of LAPS-Exendin on Body Weight in Obese Population

    Not yet reported Hanmi Pharmaceutical Company Limited 297 participants Est. completion 2015-02 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT02081118

    Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

    Not yet reported Hanmi Pharmaceutical Company Limited 209 participants Est. completion 2015-04 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT06174779

    A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus

    Not yet reported Hanmi Pharmaceutical Company Limited 448 participants Est. completion 2026-03-13 1 site Stand-alone
    Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.